PL3192874T3 - Oczyszczanie wirusa - Google Patents

Oczyszczanie wirusa

Info

Publication number
PL3192874T3
PL3192874T3 PL16002644T PL16002644T PL3192874T3 PL 3192874 T3 PL3192874 T3 PL 3192874T3 PL 16002644 T PL16002644 T PL 16002644T PL 16002644 T PL16002644 T PL 16002644T PL 3192874 T3 PL3192874 T3 PL 3192874T3
Authority
PL
Poland
Prior art keywords
virus purification
virus
purification
Prior art date
Application number
PL16002644T
Other languages
English (en)
Inventor
Richard Truran
Robert Buckley
Pippa Radcliffe
James Miskin
Kyri Mitrophanous
Original Assignee
Oxford Biomedica (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3192874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford Biomedica (Uk) Limited filed Critical Oxford Biomedica (Uk) Limited
Publication of PL3192874T3 publication Critical patent/PL3192874T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16002644T 2008-06-18 2009-06-18 Oczyszczanie wirusa PL3192874T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7368508P 2008-06-18 2008-06-18
EP09766124.3A EP2307551B1 (en) 2008-06-18 2009-06-18 Purification of retroviral vectors
PCT/GB2009/001527 WO2009153563A1 (en) 2008-06-18 2009-06-18 Virus purification
EP16002644.9A EP3192874B1 (en) 2008-06-18 2009-06-18 Virus purification

Publications (1)

Publication Number Publication Date
PL3192874T3 true PL3192874T3 (pl) 2020-06-29

Family

ID=40940324

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09766124T PL2307551T3 (pl) 2008-06-18 2009-06-18 Oczyszczanie wektorów retrowirusowych
PL16002644T PL3192874T3 (pl) 2008-06-18 2009-06-18 Oczyszczanie wirusa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09766124T PL2307551T3 (pl) 2008-06-18 2009-06-18 Oczyszczanie wektorów retrowirusowych

Country Status (8)

Country Link
US (1) US9169491B2 (pl)
EP (2) EP2307551B1 (pl)
JP (2) JP5615271B2 (pl)
CN (2) CN102124115B (pl)
DK (2) DK2307551T3 (pl)
ES (2) ES2618851T3 (pl)
PL (2) PL2307551T3 (pl)
WO (1) WO2009153563A1 (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2680915T3 (es) 2010-01-28 2018-09-11 The Children's Hospital Of Philadelphia Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
JP5965392B2 (ja) 2010-05-28 2016-08-03 オックスフォード バイオメディカ (ユーケー) リミテッド 脳へのレンチウイルスベクターの送達
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
CN104136605B (zh) 2011-11-24 2018-08-14 吉尼松公司 与工业制药应用相容的可放大的慢病毒载体生产系统
WO2013090409A1 (en) * 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
EP2852662B1 (en) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
MX364690B (es) * 2013-03-15 2019-05-06 Childrens Hospital Philadelphia Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) * 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
EP3215522B1 (en) 2014-11-03 2021-12-01 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T cell receptors directed against bob1 and uses thereof
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
WO2016142783A2 (en) 2015-03-10 2016-09-15 Leiden University Medical Center T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
ES2987957T3 (es) 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
WO2017197038A1 (en) 2016-05-10 2017-11-16 United States Government As Represented By The Department Of Veterans Affairs Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
GB201614050D0 (en) * 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
WO2019102381A1 (en) 2017-11-21 2019-05-31 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
EP3728594A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a
EP3728595A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3696272A1 (en) 2017-12-22 2020-08-19 Oxford BioMedica (UK) Limited Retroviral vector
CN113056561A (zh) * 2018-04-05 2021-06-29 牛津大学科技创新有限公司 用于治疗黄斑营养不良的组合物和方法
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
AU2019286406B2 (en) 2018-06-12 2023-04-13 Kbio Holdings Limited Virus and antigen purification and conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CN112770768A (zh) * 2018-08-16 2021-05-07 太空飞船七有限责任公司 用于病毒载体的生产方法
CA3133188A1 (en) 2019-03-10 2020-09-17 Oxford Biomedica (Uk) Limited Gene therapy compositions and methods for treating parkinson's disease
WO2020214676A1 (en) * 2019-04-15 2020-10-22 Children's Hospital Medical Center Viral vector manufacturing methods
KR20220047635A (ko) 2019-08-23 2022-04-18 론자 워커스빌 아이엔씨. 렌티바이러스 벡터의 생산을 위한 방법 및 작제물
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
JP2023513303A (ja) 2020-02-13 2023-03-30 オックスフォード バイオメディカ(ユーケー)リミテッド レンチウイルスベクターの製造
US20230118587A1 (en) 2020-03-13 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral Vectors
WO2021222222A1 (en) 2020-04-27 2021-11-04 Mccray Jr Paul B Compositions and methods for the treatment of cystic fibrosis
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
EP4196596A4 (en) * 2020-08-13 2025-01-01 Tmunity Therapeutics Inc. METHOD FOR PRODUCING A CLINICAL QUALITY LENTIVIRAL VECTOR
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
EP4222250A1 (en) * 2020-10-02 2023-08-09 Genelux Corporation Bioreactor production of virus from adherent cells
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CN112899242A (zh) * 2021-02-03 2021-06-04 苏州博腾生物制药有限公司 慢病毒纯化工艺
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
JPWO2023074877A1 (pl) 2021-10-29 2023-05-04
EP4431600A4 (en) 2021-11-12 2026-03-04 Agc Inc Virus purification method
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
CN116240241A (zh) * 2022-12-30 2023-06-09 上海本导基因技术有限公司 重组慢病毒载体的纯化制备方法
KR20250141180A (ko) * 2023-02-01 2025-09-26 인테리우스 바이오테라퓨틱스, 인코포레이티드 바이러스 입자의 여과 또는 정제를 위한 방법
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2025235738A1 (en) * 2024-05-08 2025-11-13 Interius Biotherapeutics, Inc. Methods of detecting residual dna in viral preparations

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1995019427A1 (en) * 1994-01-12 1995-07-20 Genetic Therapy, Inc. Purification of retroviral vectors
EP0751988B1 (en) 1994-03-22 2000-02-09 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
PT968182E (pt) 1996-08-07 2004-08-31 Darwin Discovery Ltd Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB2325003B (en) 1996-10-17 2000-05-10 Oxford Biomedica Ltd Rectroviral vectors
WO1999061639A2 (en) 1998-05-22 1999-12-02 Oxford Biomedica (Uk) Limited Retroviral delivery system
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (pl) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US20050118701A1 (en) * 2002-03-29 2005-06-02 Weichang Zhou Large scale methods of producing adenovirus and adenovirus seed stocks
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
ATE488252T1 (de) 2003-05-05 2010-12-15 Virxsys Corp Erhöhte transduktion mit abc- transportersubstratenhemmern
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
ES2342397T3 (es) * 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
ATE539149T1 (de) 2006-04-20 2012-01-15 Wyeth Llc Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
EP2091966A2 (en) * 2006-12-01 2009-08-26 Oxford BioMedica (UK) Limited Promoter construct
NZ578873A (en) 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
ES2622834T3 (es) * 2007-11-13 2017-07-07 Bio-Technology General (Israel) Ltd. Procedimiento de esterilización por filtración en estado diluido para biopolímeros viscoelásticos

Also Published As

Publication number Publication date
CN102124115B (zh) 2020-03-03
WO2009153563A1 (en) 2009-12-23
EP3192874B1 (en) 2019-10-16
DK3192874T3 (da) 2019-12-16
JP2011524887A (ja) 2011-09-08
ES2618851T3 (es) 2017-06-22
PL2307551T3 (pl) 2017-07-31
EP2307551A1 (en) 2011-04-13
US9169491B2 (en) 2015-10-27
ES2762864T3 (es) 2020-05-26
JP2014237661A (ja) 2014-12-18
DK2307551T3 (en) 2017-03-20
JP6002720B2 (ja) 2016-10-05
CN103993040A (zh) 2014-08-20
CN102124115A (zh) 2011-07-13
JP5615271B2 (ja) 2014-10-29
EP2307551B1 (en) 2016-12-14
CN103993040B (zh) 2018-02-13
EP3192874A1 (en) 2017-07-19
US20090325284A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
GB0807424D0 (en) Virus
EP2334328A4 (en) METHOD FOR CLEANING VIRUSES
SG10201701988TA (en) Virus like particle purification
GB0822068D0 (en) Methods for virus design
GB0807607D0 (en) Catalyst
ZA201007843B (en) Structured coauthoring
SI2398785T1 (sl) Äśiĺ äśenje 1-(2-(2,4-dimetilfenilsulfanil)fenil)-piperazina
EP2234662A4 (en) FILTERED
SI2098275T1 (sl) Filter
GB0714578D0 (en) Viruses
PL2323610T3 (pl) Chodzik
IL212646A0 (en) Immunoglobulin purification
GB0808908D0 (en) Purification process
PL2379978T3 (pl) Dystrybutor płynów z symetrią obrotową
GB0912950D0 (en) Virus
GB0818228D0 (en) Purification process
GB0720624D0 (en) Viral Modification
GB0814668D0 (en) Filter
GB0901056D0 (en) Virus
GB0917623D0 (en) Nanoparticle purification
GB0811505D0 (en) Purification process
GB0821319D0 (en) Easy walker
GB0823560D0 (en) Virus
GB0803321D0 (en) Purification unit
GB0709027D0 (en) Virus purification